Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres
The objective of this study was to demonstrate the efficacy of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus (MRSA) entrapped in alginate beads. An inoculum of 5.25 × 105 colony-forming units (CFU)/mL of S. aureus strain AH1252 was administered intratracheally to rats with prepared alginate bacteria suspensions. Beginning 2 h post-infection, rats received: (1) iclaprim 80 mg/kg (n = 16); (2) iclaprim 60 mg/kg (n = 16), or (3) vancomycin 50 mg/kg (n = 24), for 3 days via subcutaneous (SC) injection every 12 h. Twelve hours after the last treatment, rats were euthanized and lungs collected for CFU determination. Iclaprim administered at 80 mg/kg or 60 mg/kg or vancomycin 50 mg/kg SC twice a day for 3 days resulted in a 6.05 log10 CFU reduction (iclaprim 80 mg/kg compared with control, p < 0.0001), 5.11 log10 CFU reduction (iclaprim 60 mg/kg compared with control, p < 0.0001), and 3.42 log10 CFU reduction, respectively, from the controls (p < 0.0001). Iclaprim 80 mg/kg and 60 mg/kg resulted in 2.59 and 1.69 log10 CFU reductions, respectively, from vancomycin-treated animals (80 mg/kg iclaprim vs. vancomycin, p = 0.0005; 60 mg/kg iclaprim vs. vancomycin, p = 0.07). Animals receiving iclaprim, vancomycin, and controls demonstrated 100%, 91.7%, and 48.3% survival, respectively. In this neutropenic rat S. aureus lung infection model, rats receiving iclaprim demonstrated a greater CFU reduction than the controls or those receiving vancomycin.
Compliance with ethical standards
Conflict of interest
DBH is an employee of Motif BioSciences. IM and SH are employees of IHMA. TM is an employee of NeoSome Life Sciences. MHW has received consulting fees from Abbott Laboratories, Actelion, Astellas, AstraZeneca, Bayer, biomérieux, Cerexa, Cubist, Durata, The European Tissue Symposium, The Medicines Company, MedImmune, Merck, Motif BioSciences, Nabriva, Optimer, Paratek, Pfizer, Qiagen, Roche, Sanofi-Pasteur, Seres, Summit, and Synthetic Biologics; lecture fees from Abbott, Alere, Astellas, AstraZeneca, Merck, Pfizer, and Roche; and grant support from Abbott, Actelion, Astellas, bioMérieux, Cubist, Da Volterra, Micro-Pharm, Morphochem AG, Sanofi-Pasteur, Seres, Summit, The European Tissue Symposium, and Merck.
This research involved animals. All procedures in this research were in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare.
- 4.Menéndez R, Montull B, Reyes S, Amara-Elori I, Zalacain R, Capelastegui A, Aspa J, Borderías L, Martín-Villasclaras JJ, Bello S, Alfageme I, Rodríguez de Castro F, Rello J, Molinos L, Ruiz-Manzano J, Torres A (2016) Pneumonia presenting with organ dysfunctions: causative microorganisms, host factors and outcome. J Infect 73:419–426CrossRefPubMedGoogle Scholar
- 8.Huang DB, Hawser S, Gemmell CG, Sahm DF (2017) In vitro activity of iclaprim against methicillin-resistant Staphylococcus aureus nonsusceptible to daptomycin, linezolid or vancomycin. Can J Infect Dis Med Microbiol (in press)Google Scholar
- 11.Entenza JM, Haldimann A, Giddey M, Lociuro S, Hawser S, Moreillon P (2009) Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model. Antimicrob Agents Chemother 53:3635–3641CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Clinical and Laboratory Standards Institute (CLSI) (2015) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard—Tenth edition. CLSI document M07-A10. CLSI, Wayne, PA 19087-1898, USAGoogle Scholar
- 13.Clinical and Laboratory Standards Institute (CLSI) (2017) Performance standards for antimicrobial susceptibility testing; Informational supplement—Twenty-seventh edition. CLSI document M100-S27. CLSI, Wayne, PA 19087-1898, USAGoogle Scholar
- 14.Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF (1986) Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and Leukopenic rats. Antimicrob Agents Chemother 30:403–408CrossRefPubMedPubMedCentralGoogle Scholar
- 17.de Górgolas M, Avilés P, Verdejo C, Fernández Guerrero ML (1995) Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim–sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 39:953–957CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Andrews J, Honeybourne D, Ashby J, Jevons G, Fraise A, Fry P, Warrington S, Hawser S, Wise R (2007) Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J Antimicrob Chemother 60:677–680CrossRefPubMedGoogle Scholar
- 20.Huang DB, File TM Jr, Torres A, Shorr AF, Wilcox MH, Hadvary P, Dryden M, Corey GR (2017) A phase II randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin for the treatment of nosocomial pneumonia suspected or confirmed to be due to Gram-positive pathogens. Clin Ther 39:1706–1718CrossRefPubMedGoogle Scholar